» Articles » PMID: 35741001

Obesity: The Fat Tissue Disease Version of Cancer

Overview
Journal Cells
Publisher MDPI
Date 2022 Jun 24
PMID 35741001
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity is a disease with high potential for fatality. It perfectly fits the disease definition, as cancer does. This is because it damages body structure and functions, both mechanically and biologically, and alters physical, mental, and social health. In addition, it shares many common morbid characteristics with the most feared disease, cancer. For example, it is influenced by a sophisticated interaction between a person's genetics, the environment, and an increasing number of other backgrounds. Furthermore, it displays abnormal cell growth and proliferation events, only limited to white fat, resulting in adipose tissue taking up an increasing amount of space within the body. This occurs through fat "metastases" and via altered signaling that further aggravates the pathology of obesity by inducing ubiquitous dishomeostasis. These metastases can be made graver by angiogenesis, which might boost diseased tissue growth. More common features with cancer include its progressive escalation through different levels of severity and its possibility of re-onset after recovery. Despite all these similarities with cancer, obesity is substantially less agitating for most people. Thus, the ideas proposed herein could have utility to sensitize the public opinion about the hard reality of obesity. This is increasingly needed, as the obesity pandemic has waged a fierce war against our bodies and society in general, while there is still doubt about whether it is a real disease or not. Hence, raising public consciousness to properly face health issues is crucial to improving our health instead of gaining weight unhealthily. It is obviously illogical to fight cancer extremely seriously on the one hand and to consider dying with obesity as self-inflicted on the other. In fact, obesity merits a top position among the most lethal diseases besides cancer.

Citing Articles

Cannabigerol-A useful agent restoring the muscular phospholipids milieu in obese and insulin-resistant Wistar rats?.

Bielawiec P, Dziemitko S, Konstantynowicz-Nowicka K, Sztolsztener K, Chabowski A, Harasim-Symbor E Front Mol Biosci. 2024; 11:1401558.

PMID: 38919749 PMC: 11196617. DOI: 10.3389/fmolb.2024.1401558.


Investigating the alterations of endocannabinoidome signaling in the human small intestine in the context of obesity and type 2 diabetes.

Rakotoarivelo V, Allam-Ndoul B, Martin C, Biertho L, Di Marzo V, Flamand N Heliyon. 2024; 10(6):e26968.

PMID: 38515705 PMC: 10955212. DOI: 10.1016/j.heliyon.2024.e26968.


Obesity and Bone Mineral Density Protection Paradox in Chronic Kidney Disease: Secreted Protein Acidic and Rich in Cysteine as a Piece of the Puzzle?.

Ghanemi A, Mac-Way F Life (Basel). 2023; 13(11).

PMID: 38004312 PMC: 10672555. DOI: 10.3390/life13112172.


New role for the anandamide metabolite prostaglandin F ethanolamide: Rolling preadipocyte proliferation.

Boubertakh B, Courtemanche O, Marsolais D, Di Marzo V, Silvestri C J Lipid Res. 2023; 64(11):100444.

PMID: 37730163 PMC: 10622703. DOI: 10.1016/j.jlr.2023.100444.


Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.

Tseng C Front Endocrinol (Lausanne). 2023; 14:1185053.

PMID: 37560306 PMC: 10407244. DOI: 10.3389/fendo.2023.1185053.


References
1.
Hanckova M, Betakova T . Pandemics of the 21st Century: The Risk Factor for Obese People. Viruses. 2022; 14(1). PMC: 8779521. DOI: 10.3390/v14010025. View

2.
Polyzos S, Kountouras J, Mantzoros C . Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2018; 92:82-97. DOI: 10.1016/j.metabol.2018.11.014. View

3.
Stein J, Luppa M, Ruzanska U, Sikorski C, Konig H, Riedel-Heller S . Measuring negative attitudes towards overweight and obesity in the German population - psychometric properties and reference values for the German short version of the Fat Phobia Scale (FPS). PLoS One. 2014; 9(12):e114641. PMC: 4256451. DOI: 10.1371/journal.pone.0114641. View

4.
Berenbaum F, Eymard F, Houard X . Osteoarthritis, inflammation and obesity. Curr Opin Rheumatol. 2012; 25(1):114-8. DOI: 10.1097/BOR.0b013e32835a9414. View

5.
Mortera R, Bains Y, Gugliucci A . Fructose at the crossroads of the metabolic syndrome and obesity epidemics. Front Biosci (Landmark Ed). 2018; 24(2):186-211. DOI: 10.2741/4713. View